Abstract
An inhibitor of xanthine oxidase (XO)/xanthine dehydrogenase (XDH), an enzyme catalyzing the last step of purine catabolism, might be expected to be effective as remedy for hyperuricemia and possibly for ischemia-reperfusion injury. However, no clinically effective XO/XDH inhibitor except allopurinol have been used since it was introduced for clinical use in 1962 (1, 2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.B. Elion, S. Callahan, H. Nathan, S. Bieber, R.W. Rundles and G.H. Hitchings, Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase, Biochem. Pharmacol. 12, 85–93 (1963)
R. Hille and V. Massey, Tight binding inhibitors of xanthine oxidase, Pharmac. Ther. 14, 249–263 (1981)
V. Massey, H. Komai and G. Palmer, On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3, 4-d] pyrimidines, J. Biol. Chem. 245 (11), 2837–2844 (1970)
D.A. Parks and D.N. Granger, Xanthine oxidase: biochemistry, distribution and physiology, Acta Physiol. Scand. Suppl. 548, 87–99 (1986)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sato, S., Tatsumi, K., Nishino, T. (1991). A Novel Xanthine Dehydrogenase Inhibitor (BOF-4272). In: Harkness, R.A., Elion, G.B., Zöllner, N. (eds) Purine and Pyrimidine Metabolism in Man VII. Advances in Experimental Medicine and Biology, vol 309A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2638-8_30
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2638-8_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2640-1
Online ISBN: 978-1-4899-2638-8
eBook Packages: Springer Book Archive